The ATP-gated P2X7 receptor (P2X7R) is a non-selective cation channel which senses high extracellular ATP concentrations and has been suggested as a target for the treatment of neuroinflammation and neurodegenerative diseases. The use of P2X7R antagonists may therefore be a viable approach for treating CNS pathologies, including epileptic disorders. Recent studies showed anticonvulsant potential of P2X7R antagonists in certain animal models. To extend this work, we tested three CNS-permeable P2X7R blocker (Brilliant Blue G, AFC-5128, JNJ-47965567) and a natural compound derivative (tanshinone IIA sulfonate) in four well-characterized animal seizure models. In the maximal electroshock seizure threshold test and the pentylenetetrazol (PTZ) seizure threshold test in mice, none of the four compounds demonstrated anticonvulsant effects when given alone. Notably, in combination with carbamazepine, both AFC-5128 and JNJ-47965567 increased the threshold in the maximal electroshock seizure test. In the PTZ-kindling model in rats, useful for testing antiepileptogenic activities, Brilliant Blue G and tanshinone exhibited a moderate retarding effect, whereas the potent P2X7R blocker AFC-5128 and JNJ-47965567 showed a significant and long-lasting delay in kindling development. In fully kindled rats, the investigated compounds revealed modest effects to reduce the mean seizure stage. Furthermore, AFC-5128- and JNJ-47965567-treated animals displayed strongly reduced Iba 1 and GFAP immunoreactivity in the hippocampal CA3 region. In summary, our results show that P2X7R antagonists possess no remarkable anticonvulsant effects in the used acute screening tests, but can attenuate chemically-induced kindling. Further studies would be of interest to support the concept that P2X7R signalling plays a crucial role in the pathogenesis of epileptic disorders.

The ATP-gated P2X7 receptor (P2X7R) is a non-selective cation channel which senses high extracellular ATP concentrations and has been suggested as a target for the treatment of neuroinflammation and neurodegenerative diseases. The use of P2X7R antagonists may therefore be a viable approach for treating CNS pathologies, including epileptic disorders. Recent studies showed anticonvulsant potential of P2X7R antagonists in certain animal models. To extend this work, we tested three CNS-permeable P2X7R blocker (Brilliant Blue G, AFC-5128, JNJ-47965567) and a natural compound derivative (tanshinone IIA sulfonate) in four well-characterized animal seizure models. In the maximal electroshock seizure threshold test and the pentylenetetrazol (PTZ) seizure threshold test in mice, none of the four compounds demonstrated anticonvulsant effects when given alone. Notably, in combination with carbamazepine, both AFC-5128 and JNJ-47965567 increased the threshold in the maximal electroshock seizure test. In the PTZ-kindling model in rats, useful for testing antiepileptogenic activities, Brilliant Blue G and tanshinone exhibited a moderate retarding effect, whereas the potent P2X7R blocker AFC-5128 and JNJ-47965567 showed a significant and long-lasting delay in kindling development. In fully kindled rats, the investigated compounds revealed modest effects to reduce the mean seizure stage. Furthermore, AFC-5128- and JNJ-47965567-treated animals displayed strongly reduced Iba 1 and GFAP immunoreactivity in the hippocampal CA3 region. In summary, our results show that P2X7R antagonists possess no remarkable anticonvulsant effects in the used acute screening tests, but can attenuate chemically-induced kindling. Further studies would be of interest to support the concept that P2X7R signalling plays a crucial role in the pathogenesis of epileptic disorders.

De nombreuses études expérimentales montrent que les canaux calciques activés par la dépolarisation membranaire, tout particulièrement les canaux calciques de type T (canaux T), jouent un rôle important dans la physiopathologie des épilepsies. Il existe trois isoformes des canaux T, Cav3.1, Cav3.2 et Cav3.3, toutes exprimées au niveau neuronal. De manière classique, c'est dans l'épilepsie absence où les canaux T ont été le plus étudiés. Les canaux T jouent également un rôle dans des modèles d'épilepsie partielle secondairement généralisée, comme le modèle pilocarpine qui mime l'épilepsie du lobe temporal (ELT). Jusqu'à présent ces canaux ne possédaient pas de pharmacologie spécifique, mais plusieurs molécules récemment synthétisées, en particulier le TTA-A2, apparaissent sélectives des canaux T. Le premier objectif de ma thèse était d'étudier l'implication des canaux T dans l'épileptogenèse. Pour cela nous avons traité des souris au TTA-A2 pendant la phase de latence du modèle pilocarpine (modèle ELT). Nos conditions expérimentales ne nous ont pas permis de conclure quant à une action protectrice du TTA-A2 dans ce modèle. Le deuxième objectif était d'étudier l'effet du TTA-A2 sur des modèles murins de convulsions généralisées : le modèle du Maximal Electroshock Seizure (MES) et le modèle pentylènetétrazole (PTZ). Deux lignées de souris inactivées pour les isoformes Cav3.1 ou Cav3.2 (KO Cav3.1 et KO Cav3.2) ont également été caractérisées dans cette étude. Nous montrons que le TTA-A2 réduit l'apparition des crises toniques dans le modèle MES et que les souris KO Cav3.1 sont également protégées, suggérant un rôle prépondérant des canaux Cav3.1 dans le développement des crises toniques. / Numerous experimental studies show that calcium channels activated by membrane depolarization, especially T-type calcium channels (T-channels), play an important role in the physiopathology of epilepsy. There are three T-channels isoforms, Cav3.1, Cav3.2 and Cav3.3, all expressed in neuronal level. Conventionally, T-channels were the most studied in absence epilepsy. T-channels are also involved in partial secondarily generalized epilepsy models, as the pilocarpine model that mimics temporal lobe epilepsy (TLE).Up to now, there was no specific pharmacology for this channels, but several molecules have recently been synthesized, particularly TTA-A2, appearing selective T-channels. The first goal of my thesis was to study the T-channels involvement in epileptogenesis. For this purpose we treated mice with TTA-A2 during the silent phase of the pilocarpine model (TLE model). Our experimental conditions do not allow us to conclude about a possible protective action of TTA-A2 on this model. The second goal was to study TTA-A2 effects on mice models of generalized seizures: the Maximal Electroshock model (MES) and the pentylenetetrazole model (PTZ). Two mice strains knock-out for Cav3.1 or Cav3.2 (KO Cav3.1 and KO Cav3.2) have also been characterized in this study. We show that the TTA-A2 reduces the appearance of tonic seizures in the MES model and the KO Cav3.1 mice are also protected, suggesting a preponderant role of Cav3.1 channels in the development of tonic seizures.